Uric acid relates to dopamine transporter availability in Parkinson's disease

Moccia, Marcello; Pappatà, Sabina; Erro, Roberto; Picillo, Marina; Vitale, Carmine; Amboni, Marianna; Longo, Katia; Palladino, Raffaele; Barone, Paolo; Pellecchia, Maria Teresa

doi:10.1111/ane.12295

Cited by 31 publications

(21 citation statements)

References 15 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study found no correlation between UA levels and disease severity in untreated PD patients, but found that lower UA levels were significantly associated with lower dopamine transporter binding in the caudate, putamen, and striatum (Moccia et al., 2015). Meamar, Shaabani, Tabibian, Aghaye Ghazvini, and Feizi (2015) observed positive but statistically insignificant correlations of serum UA levels with HY stage and UPDRS part III in PD patients using regression models and found a positive relationship between serum UA levels and UPDRS part III in PD patients aged 62 years or younger.…”

Section: Discussionmentioning

confidence: 99%

“…(2015) found a relation between serum UA and dopamine transporter availability in drug‐naïve PD patients: serum UA levels were positively correlated with averaged, ipsilateral and contralateral dopamine transporter binding in the striatum, specifically in the caudate and putamen. In PD patients, low serum UA levels have been associated with cognitive dysfunction (Annanmaki, Pessala‐Driver, Hokkanen, & Murros, 2008).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum uric acid levels in Parkinson's disease and related disorders

et al. 2016

View full text Add to dashboard Cite

ObjectiveSerum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA). However, clinical correlates of serum UA levels are still unclear in PD‐related disorders. We conducted a cross‐sectional study to evaluate the associations between serum UA levels and disease duration, disease severity, and motor function among PD, MSA, and progressive supranuclear palsy (PSP) patients.MethodsA total of 100 patients with PD, 42 patients with MSA, 30 patients with PSP, and 100 controls were included in this study. Serum UA levels were determined, and associations among serum UA levels and disease duration, disease severity, and motor function in PD, PSP, and MSA patients were evaluated.ResultsSerum UA levels were significantly lower in male PD, MSA, and PSP patients compared with the controls, but not in female patients. Serum UA levels were negatively correlated with disease duration and severity in MSA and PSP patients, but no correlations were observed in PD patients. The serum UA levels were significantly decreased in the tauopathy group (PSP patients) compared with the synucleinopathy group (PD and MSA patients) after adjusting for age, gender, and body mass index.ConclusionWe found decreased serum UA levels in male patients with PD‐related disorders (PD, MSA, and PSP) compared with male controls, and significant correlations between serum UA levels and disease severity in MSA and PSP patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum uric acid levels in Parkinson's disease and related disorders

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[4][5][6] Previous studies have demonstrated that low levels of serum UA are involved in the pathogenesis and disease progression of PD, although its sensitivity as a single biomarker for PD is low. [7][8][9][10][11][12][13] Case-series studies in PD have also found that low levels of serum UA are associated with a higher severity of motor symptoms and a higher presence of nonmotor symptoms. 14 Moreover, a recent study has demonstrated that higher levels of serum UA may be associated with a longer duration of rapid eye movement sleep behavior disorders without converting to PD.…”

mentioning

confidence: 98%

Low serum uric acid levels in progressive supranuclear palsy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Oxidative stress has been linked to dopamine cell neurodegeneration and is related to the susceptibility for developing Parkinson's disease (PD) . Several studies have found that uric acid levels significantly correlate with the severity of dopaminergic impairment in the striatum . High plasma urate concentrations are lower in PD than in controls, and urate levels are related to the progression of PD .…”

mentioning

confidence: 99%

Relationship between uric acid levels and progressive supranuclear palsy

et al. 2016

View full text Add to dashboard Cite

Background The pathophysiology of both Parkinson’s disease (PD) and progressive supranuclear palsy is characterized by a pro-oxidant state. Uric acid is an oxidative stress marker. High uric acid blood levels have been associated with a reduced risk of PD and a decreased rate of disease progression. We investigated whether a low serum concentration of uric acid is also associated with progressive supranuclear palsy. Methods We measured serum uric acid concentrations in a subsample of the ENGENE progressive supranuclear palsy Cohort that included 75 cases and 75 frequency-matched-by-sex healthy controls (69 spouses, 6 in-laws) from 4 centers willing to participate (Case Western, Rush University, University of Utah, and University of Louisville). Case severity was characterized using the total progressive supranuclear palsy-Rating Scale, Unified PD Rating Scale and Mattis Dementia Rating Scale. Unconditional logistic regression, Pearson’s chi-squared test and Analysis of Variance were used as appropriate. Results The mean uric acid level among cases (4.0 mg/dl) was not significantly lower than that of controls (4.1 mg/dl). When controlling for sex, there were no between-group statistical differences in uric acid levels. Uric acid levels were not correlated with disease severity. Conclusion The results of this study do not provide evidence of uric acid having a protective role in progressive supranuclear palsy, even if oxidative injury is important in the pathophysiology of this disorder. The lack of statistical significance suggests that there is no direct association between uric acid levels and progressive supranuclear palsy. However, a small inverse association cannot be excluded.

show abstract

Uric acid relates to dopamine transporter availability in Parkinson's disease

Cited by 31 publications

References 15 publications

Serum uric acid levels in Parkinson's disease and related disorders

Serum uric acid levels in Parkinson's disease and related disorders

Low serum uric acid levels in progressive supranuclear palsy

Relationship between uric acid levels and progressive supranuclear palsy

Contact Info

Product

Resources

About